Jefferies provides research and execution services in equity, fixed income, and foreign exchange markets.
Business Model:
Revenue: $6B
Employees: 5,001-10,000
Jefferies was acquired by
Jefferies Financial Group.
The acquisition happend on 2012-11-12.
Details of the transaction were not public
Address: 520 Madison Ave
City: New York
State: NY
Zip: 10022
Country: US
Jefferies provides research and execution services in equity, fixed income, and foreign exchange markets. Jefferies, a major global securities and investment banking group, has served companies and their investors for nearly 50 years and operates in more than 25 cities around the world. They provide world-class investment banking, sales and trading, research and asset management to a diverse range of corporate clients, institutional investors and high net worth individuals. They are industry experts, specializing in aerospace and defense, consumer energy, financial services, gaming and leisure, healthcare, industrials, maritime, media, real estate &a; lodging, technology, and telecommunications, with a dedicated private equity coverage group.
Contact Phone:
+12122842300
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2018 | Petal | Debt Financing | 34M |
1/2018 | Visible Alpha | Venture Round | 38M |
10/2017 | Abeona Therapeutics | Post-IPO Equity | 0 |
6/2014 | Ablynx | Post-IPO Equity | 0 |
10/2018 | Ualá | Series B | 0 |
8/2016 | Advaxis | Post-IPO Equity | 0 |
10/2014 | Symphony Communication Services | Series A | 66M |
4/2018 | CloudMargin | Venture Round | 10M |
1/2000 | Enterworks Acquisition Inc. | Venture Round | 25M |
5/2019 | Figure | Debt Financing | 0 |
7/2022 | Illuminate Financial | Venture Round | - |
3/2022 | NextRNA Therapeutics | Series A | 0 |
3/2016 | Liminal BioSciences | Post-IPO Debt | 30M |
2/2022 | Superpedestrian | Series C | 0 |
1/2019 | dv01 | Series B | 15M |
7/2014 | Aura Financial | Series B | 0 |
3/2000 | THINQ Learning Solutions | Series C | 0 |
3/2011 | BONDS.COM | Venture Round | 0 |
2/2017 | Bond Street | Debt Financing | 300M |
6/2016 | dv01 | Convertible Note | 5M |
1/2017 | Ualá | Seed Round | - |
2/2022 | Superpedestrian | Debt Financing | - |
4/2015 | Avant | Debt Financing | 400M |
9/2017 | Ualá | Convertible Note | - |
9/2019 | Petal | Debt | 300M |
5/2015 | Affirm | Series B | 275M |
6/2015 | Bond Street | Series A | 10M |
2/2018 | Ualá | Series A | 10M |
4/2016 | Affirm | Series D | 100M |
6/2015 | Bond Street | Debt Financing | 100M |
8/2014 | Avant | Debt Financing | 200M |
3/2000 | 1800wedding.com | Series C | 10.4M |
6/2021 | Entrinsic Bioscience | Debt Financing | 49M |
7/2022 | Illuminate Financial | Venture Round | - |
3/2022 | NextRNA Therapeutics | Series A | 0 |
2/2022 | Superpedestrian | Debt Financing | - |
2/2022 | Superpedestrian | Series C | 0 |
6/2021 | Entrinsic Bioscience | Debt Financing | 0 |
9/2019 | Petal | Debt Financing | 0 |
5/2019 | Figure | Debt Financing | 0 |
1/2019 | dv01 | Series B | 0 |
10/2018 | Ualá | Series B | 0 |
10/2018 | Petal | Debt Financing | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|